Pancreatic Cancer Research

ResearcherQueen Mary University of LondonActive in the last 2 years

Claude Chelala

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-2488-0669; OpenAlex author ID A5072249752. Sources: OpenAlex.

Their work

Papers
23 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
58
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 3 papers · 2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 1 paper · 2020: 1 paper · 2021: 3 papers · 2022: 4 papers · 2023: none · 2024: 1 paper · 2025: 2 papers · 2026: 1 paper

Papers 23

  1. Systematic benchmarking of low-input whole exome sequencing workflows for longitudinal ctDNA profiling in pancreatic ductal adenocarcinoma Last author DOI 10.64898/2026.06.29.734743↗
  2. AHNAK2: a potential diagnostic biomarker for pancreatic cancer related to cellular motility. Co-author DOI 10.1038/s41598-025-87337-5↗
  3. Study protocol: multi-centre, randomised controlled clinical trial exploring stromal targeting in locally advanced pancreatic cancer; STARPAC2. Co-author DOI 10.1186/s12885-024-13333-z↗
  4. Prognostication for recurrence patterns after curative resection for pancreatic ductal adenocarcinoma. Co-author DOI 10.14701/ahbps.23-149↗
  5. The molecular landscape of pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.pan.2022.07.010↗
  6. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy. Co-author DOI 10.1080/2162402x.2022.2080329↗
  7. Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer. Last author DOI 10.1186/s12885-022-09387-6↗
  8. Differentiating Ductal Adenocarcinoma of the Pancreas from Benign Conditions Using Routine Health Records: A Prospective Case-Control Study. Co-author DOI 10.3390/cancers15010280↗
  9. Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application. Last author DOI 10.1016/j.pan.2020.12.017↗
  10. Correction: A Virus-infected, Reprogrammed Somatic Cell-derived Tumor Cell (VIReST) Vaccination Regime can Prevent Initiation and Progression of Pancreatic Can… Co-author DOI 10.1158/1078-0432.ccr-21-0850↗
  11. Temporality of clinical factors associated with pancreatic cancer: a case-control study using linked electronic health records. Co-author DOI 10.1186/s12885-021-09014-w↗
  12. A Virus-Infected, Reprogrammed Somatic Cell-Derived Tumor Cell (VIReST) Vaccination Regime Can Prevent Initiation and Progression of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-1395↗
  13. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Co-author DOI 10.1002/path.5320↗
  14. Splice variants as novel targets in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-017-03354-z↗
  15. Reduced Expression of Histone Methyltransferases KMT2C and KMT2D Correlates with Improved Outcome in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-16-0481↗
  16. Pancreatic cancer tissue banks: where are we heading? Co-author DOI 10.2217/fon-2016-0243↗
  17. Noninvasive urinary miRNA biomarkers for early detection of pancreatic adenocarcinoma. Co-author PMID 26807325↗
  18. A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s13073-014-0105-3↗
  19. S100P is a metastasis-associated gene that facilitates transendothelial migration of pancreatic cancer cells. First author DOI 10.1007/s10585-012-9532-y↗
  20. Activated pancreatic stellate cells sequester CD8+ T cells to reduce their infiltration of the juxtatumoral compartment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1053/j.gastro.2013.07.025↗
  21. Molecular analysis of precursor lesions in familial pancreatic cancer. First author DOI 10.1371/journal.pone.0054830↗
  22. S100P-binding protein, S100PBP, mediates adhesion through regulation of cathepsin Z in pancreatic cancer cells. First author DOI 10.1016/j.ajpath.2011.12.031↗
  23. Using BioMart as a framework to manage and query pancreatic cancer data. Last author DOI 10.1093/database/bar024↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hemant Mahendrakumar Kocher · 17 shared papers, 2012–2026 · strength 2.44
  2. Abu Z M Dayem Ullah · 4 shared papers, 2016–2024 · strength 0.64
  3. Lavanya Sivapalan · 3 shared papers, 2021–2022 · strength 0.60
  4. Christine Hughes · 3 shared papers, 2022–2025 · strength 0.59
  5. Barts Pancreas Tissue Bank · 2 shared papers, 2024–2025 · strength 0.51
  6. Mohamed Zardab · 2 shared papers, 2022–2025 · strength 0.40
  7. Jun Wang · 6 shared papers, 2013–2021 · strength 0.36
  8. L C James · 1 shared paper, 2026 · strength 0.33
  9. Cecilia H Morel · 1 shared paper, 2026 · strength 0.33
  10. Louisa S. Chard · 3 shared papers, 2020–2022 · strength 0.32
  11. Yaohe Wang · 3 shared papers, 2020–2022 · strength 0.32
  12. Richard Philip Grose · 2 shared papers, 2016–2025 · strength 0.31
  13. David Kuang-Fu Chang · 2 shared papers, 2019–2025 · strength 0.26
  14. Andrew Teck Wee Ang · 1 shared paper, 2024 · strength 0.26
  15. Tatjana Crnogorac‐Jurcevic · 6 shared papers, 2012–2017 · strength 0.25
  16. Vickna Balarajah · 2 shared papers, 2016–2022 · strength 0.19
  17. David J. Propper · 1 shared paper, 2025 · strength 0.19
  18. Fieke E. M. Froeling · 1 shared paper, 2025 · strength 0.19
  19. Debashis Sarker · 1 shared paper, 2025 · strength 0.19
  20. Khurum Hayat Khan · 1 shared paper, 2025 · strength 0.19
  21. Mairead Geraldine McNamara · 1 shared paper, 2025 · strength 0.19
  22. Pippa G. Corrie · 1 shared paper, 2025 · strength 0.19
  23. John F. Marshall · 4 shared papers, 2012–2019 · strength 0.18
  24. Shuangshuang Lu · 2 shared papers, 2020–2021 · strength 0.17
  25. Aldo Scarpa · 3 shared papers, 2014–2019 · strength 0.17

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.